Global Transdermal Patch Market and Clinical Pipeline Outlook 2022

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink: https://www.kuickresearch.com/report-global-transdermal-patch-market-and-clinical-pipeline-outlook-2022.php

 

Table of Contents

 

1. Introduction to Transdermal Patch

2. Classification of Transdermal Patches

  2.1 Single/ Multiple-Layer Drug-in-Adhesive

  2.2 Reservoir Transdermal Patches

  2.3 Matrix Based Transdermal Patches

  2.4 Vapor Patch

  2.5 Active and Passive Patch

3. Why There Exist Need for Transdermal Patches?

4. Mechanism of Transdermal Patch Drug Delivery

  4.1 Properties of Transdermal Therapeutics

  4.2 Components of Transdermal Patch

  4.3 Mechanism of Motion Sickness, Nicotine and Female Contraceptive Transdermal Patch

5. Transdermal Patch v/s Traditional Drug Delivery Methods

6. Global Transdermal Patch Market Outlook

  6.1 Global Market Scenario

  6.2 Regional Trends

7. Global Transdermal Patch Clinical Pipeline Overview

  7.1 By Phase

  7.2 By Region/Country

  7.3 By Drug Class/Molecule

  7.4 By Company

  7.5 By Orphan and Fast Track Status

  7.6 By Mode of Action

8. Global Transdermal Patch Market Dynamics

  8.1 Favorable Market Parameters

  8.2 Commercialization Challenges

9. Global Transdermal Patch Market Future Prospects

10. Global Transdermal Patch Clinical Insight

  10.1 Unknown

  10.2 Research

  10.3 Preclinical

  10.4 Clinical

  10.5 Phase-I

  10.6 Phase-I/II

  10.7 Phase-II

  10.8 Phase-II/III

  10.9 Phase-III

  10.10 Preregistration

  10.11 Registered

11. Marketed Transdermal Patch Clinical Insight by Company, Indication and Phase

12. Competitive Landscape

  12.1 3M Pharmaceuticals

  12.2 Acrux

  12.3 Agile Therapeutics

  12.4 Allergan

  12.5 ANI Pharmaceuticals

  12.6 Antares Pharma

  12.7 Bayer HealthCare Pharmaceuticals

  12.8 Corium International

  12.9 Chase Pharmaceuticals

  12.10 DURECT Corporation

  12.11 Endo Pharmaceuticals

  12.12 Fempharm

  12.13 Hisamitsu Pharmaceutical

  12.14 Immune Pharmaceuticals

  12.15 Imprimis Pharmaceuticals

  12.16 Ipsen Bioscience

  12.17 Johnson and Johnson

  12.18 LaSalle Laboratories

  12.19 Lavipharm-increase

  12.20 MINRAD International

  12.21 NeurogesX

  12.22 Noven Pharmaceuticals

  12.23 NuPathe

  12.24 Nuvo Research

  12.25 Novartis

  12.26 Pain Therapeutics

  12.27 ProStrakan

  12.28 Purdue Pharma

  12.29 Sanofi

  12.30 Scilex Pharmaceuticals

  12.31 Senju Pharmaceutical

  12.32 Somerset Pharmaceuticals

  12.33 Teikoku Seiyaku

  12.34 Therapeutic Discovery Corporation

  12.35 Transdermal Delivery Solutions Corp

  12.36 UCB-full form

  12.37 Xel Pharmaceuticals

  12.38 Zosano Pharma

 

Figure 1-1: Steps Involved in Transdermal Permeation

Figure 1-2: Ideal Properties of Transdermal Patch

Figure 2-1: Types of Commercially Available Transdermal Patch

Figure 4-1: Properties of Transdermal Therapeutics

Figure 4-2: Components of Transdermal Patch

Figure 4-3: Types of Permeation Enhancers

Figure 4-4: Schematic Representation of Iontophoresis

Figure 4-5: Mechanism of Scopolamine Transdermal Patch

Figure 4-6: Mechanism of Nicotine Transdermal Patch

Figure 4-7: Mechanism of Female Contraceptive Transdermal Patch

Figure 5-1: Issues with Traditional Drug Delivery Methods

Figure 5-2: Advantages of Transdermal  Patch

Figure 5-3: Consistent Drug Supply by Transdermal Patch

Figure 6-1: Global andndash; Transdermal Patch Market Opportunity (US$ Billion), 2016-2022

Figure 7-1: Global andndash; Transdermal Patch Pipeline by Phase (%), 2017 till 2022

Figure 7-2: Global andndash; Transdermal Patch Pipeline by Phase (Number), 2017 till 2022

Figure 7-3: Global andndash; Transdermal Patch Pipeline by Phase (%), 2017 till 2022

Figure 7-4: Global andndash; Transdermal Patch Pipeline by Phase (Number), 2017 till 2022

Figure 7-5: Global – Transdermal Patch Pipeline by Region (%), 2017 till 2022

Figure 7-6: Global – Transdermal Patch Pipeline by Country (%), 2017 till 2022

Figure 7-7: Global – Transdermal Patch Pipeline by Drug Class/Molecule (%), 2017 till 2022

Figure 7-8: Global – Transdermal Patch Pipeline by Company (%), 2017 till 2022

Figure 7-9: Global – Transdermal Patch Pipeline by Ophan and Fast Track Status (%), 2017 till 2022

Figure 7-10: Global – Transdermal Patch Pipeline by Mode of Action (%), 2017 till 2022

Figure 8-1: Drivers for Transdermal Patch

Figure 8-2: Transdermal Patch Market Commercialization Challenges

Figure 12-1: Acrux Clinical Pipeline

Figure 12-2: Agile Therapeutics Clinical Pipeline

Figure 12-3: Antares Pharma Clinical Pipeline

Figure 12-4: Corium International Clinical Pipeline

Figure 12-5: Durect Corporation Clinical Pipeline

Figure 12-6: Endo Pharmaceuticals Clinical Pipeline

Figure 12-7: Immune Pharmaceuticals Clinical Pipeline

Figure 12-8: Novartis Clinical Pipeline

Figure 12-9: Senju Pharmaceuticals Clinical Pipeline

Figure 12-10: Xel Pharamaceuticals Clinical Pipeline

Figure 12-11: Zosano Pharma Clinical Pipeline

 

 

Table 2-1: Differences between Active and Passive Transdermal Patches

Table 4-1: Transdermal Patches for Various Disease Indications

Table 12-1: Pain Therapeutics Clinical Pipeline